Prokip Gordiichuk

Prof. Dr. Prokip Gordiichuk


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Contemporary Oncology
Verified
Journal Article
Open access
PGProkip Gordiichuk
Prokip Gordiichuk
OKOleksandr Kliusov
Oleksandr Kliusov
MGMykola Gordiichuk
Mykola Gordiichuk
AKAndrii Kondratenko
Andrii Kondratenko
OPOlga Ponomarova
Olga Ponomarova
ICIvan Chervynskyy
Ivan Chervynskyy
Introduction Providing oncological care in conflict conditions is a difficult test for the country’s health care system, especially if aggression is carried out in violation of the main international rules of conduct of war, the treaties of the Geneva Convention, when the aggressor attacks the...

26 May 2023 in Experimental Oncology
Verified
Journal Article
Open access
PGProkip Gordiichuk
Prokip Gordiichuk
MGM. Gordiichuk
M. Gordiichuk
Advances implemented in the complex treatment of distal rectal cancer led to a decrease in the number of loco-regional recurrences to 5–10%, but high rates of distant metastases remain at up to 30%. They lead to disappointing long-term oncological results, which requires the search for improvement of each of the stages of complex treatment. As a consequence of the questionable effectiveness of adjuvant polychemotherapy for distal rectal cancer, the question of the possibility of transferring drug treatment from an adjuvant to a neoadjuvant regimen is reasonably raised. The presented options for full neoadjuvant therapy have been developed and tested in leading oncology centers and are based on National Comprehensive Cancer Network Version 1.2022 recommendations. It is premature to make categorical conclusions regarding the recommendation of one or another variant of their implementation. Our preliminary clinical results confirmed the need for an additional stage of restaging in the second option, after 16 weeks of polychemotherapy before chemoradiation, in order to exclude the generalization of the disease. Therefore, there is a need for a prospective, controlled intercentre study to answer some unresolved questions.

31 May 2024 in Family medicine. European practices
Verified
Journal Article
Open access
PDF file
RMRaisa Moiseenko
Raisa Moiseenko
OKOleksii Kalachov
Oleksii Kalachov
PGProkip Gordiichuk
Prokip Gordiichuk
AKAndrii Kondratenko
Andrii Kondratenko
AKAnna Konysheva
Anna Konysheva
АСАнастасія Самусєва
Анастасія Самусєва
The city of Kyiv is characterized by a high level (258.6 cases per 100,000 population) of cancer incidence and mortality. The objective: to determine the problem and prospects of providing inpatient oncology care based on the experience of the department of the Kyiv City Clinical Oncology Center (KCCOC). Materials and methods. A retrospective analysis of the work of the palliative care department of communal non-commercial enterprise “KCCOC” for 2001–2023 was carried out. The center includes a 25-bed hospital and mobile palliative care teams. A multidisciplinary approach was the basis of providing palliative care to an incurable cancer patient. Results. During this period 9,164 cancer patients in the terminal stage with high mortality rate (81.04%) received inpatient care. The average duration of stay in the hospital was 17.7 bed-days. Approximately 6% of patients readmit to the department, some of them – 3-4 times. Approximately 94% of hospitalized patients had a pain syndrome, 86% of patients received opioid analgesia. During this period, mobile palliative care teams registered and served 3,124 cancer patients, among whom 62% of patients were transferred after inpatient treatment, more than 5,700 primary visits were made. The clinical route of the palliative patient was developed and improved, which made it possible to optimize palliative care for a seriously ill oncological patient. The peculiarities of providing palliative care to incurable oncological patients in the conditions of martial law have been determined. Conclusions. Comprehensive palliative care should be a unified system of mobile and stationary care, which will make possible to control the somatic condition of the palliative patient, correct the symptoms of the disease, provide long-term support to the patient at home, which is economically feasible, allows to provide care to a larger number of patients and hospitalize in time if it is necessary. The creation of an extensive system of mobile palliative care is promising in improvement of palliative care for oncology patients (it will reduce the burden on general somatic hospitals and inpatient palliative departments), as well as qualitatively improve the provision of palliative care to patients in the primary care network.

29 December 2025 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
PGProkip Gordiichuk
Prokip Gordiichuk
ДМД.о. Морський
Д.о. Морський
SKS.I. Kirkilevsky
S.I. Kirkilevsky
MGMykola Gordiichuk
Mykola Gordiichuk
ПКП.о. Король
П.о. Король
СКС.і. Кіркілевський
С.і. Кіркілевський
Background. Gastric cancer is more frequently diagnosed at an advanced stage; in Ukraine, nearly 60% of patients have stage III or IV disease at the time of diagnosis, when surgical treatment is either inappropriate or not feasible. Conventional chemotherapy provides only limited improvement in survival; therefore, interest in targeted therapy and immunotherapy as promising treatment modalities is increasing. Purpose – was to present the results of histological, immunohistochemical, and molecular genetic characteristics of gastric cancer and the tumor microenvironment as predictors of prognosis and selection of systemic medical treatment. Materials and Methods. Data retrieval for the review was conducted in accordance with the PRISMA-ScR guidelines. A systematic search was performed in PubMed, Scopus, Google Scholar, and Embase (from 2017 to the present) and was supplemented by a review of major clinical guidelines (NCCN, ESMO) published over the past five years. Results. The results of the literature search over the past ten years demonstrated that an integrated assessment of histological and immunohistochemical characteristics enables more accurate classification of gastric cancer, prediction of its biological aggressiveness, and selection of individualized therapeutic approaches. Moreover, morphological analysis of the tumor – stroma ratio at the invasive front allows for a more precise interpretation of the clinical significance of the tumor microenvironment (TME) and facilitates the identification of novel prognostic markers associated with gastric cancer progression. Molecular genetic characteristics of the tumor (HER2 status, PD-L1 expression [CPS], MSI/MMR status, EBV positivity, and CLDN18.2 expression) determine the feasibility of personalized therapy. In metastatic gastric cancer, the integration of molecular profiling with TME characteristics enables a rational choice among anti-HER2 strategies, antiangiogenic therapy, immunotherapy, or their combinations. Conclusions. Comprehensive characterization of the tumor microenvironment, along with the immunohistochemical and molecular genetic landscape of the tumor stage IVa,b gastric cancer, should become a standard of clinical practice to enable personalized systemic therapy and improve survival outcomes.

3 July 2023 in International Journal of Surgery Oncology
Verified
Journal Article
Open access
PGProkip Gordiichuk
Prokip Gordiichuk
MGMykola Gordiichuk
Mykola Gordiichuk
Introduction: The increase in mid-ampullary and lower ampullary rectal cancer with disappointing treatment results requires ongoing discussion, research, and improvement of the complex treatment. Materials and methods: We analyzed the results of complex treatment in 442 patients with stages II–III mid-ampullary and lower ampullary rectal cancer that underwent three types of sphincter-sparing surgeries, including low anterior resection (LAR), intersphincteric resection (ISR), and abdomino-anal resection of the rectum (AAR) at the second stage of complex treatment. Results: There was a significant difference between groups in terms of surgery type selection based on the distance from the tumor to the dentate line. When the tumor was located at a distance of 30 mm or less from the dentate line, LAR was performed in 16.4% of cases, whereas ISR and AAR were used in 96.58 and 58.09% of cases, respectively, which is statistically significant (P<0.001). Preventive stoma was used in 78.87% of LAR, 5.9% of ISR, and 6.62% of AAR, which had a significant difference (P0.05), but had a direct correlation with the recurrence-free survival curves. Relapse-free and overall (3 years and 5 years) survival depending on the type of sphincter-preserving surgery did not have a significant difference according to the log-rank test. Conclusion: The more types of surgical intervention surgeons have at their disposal, the more rational it is to select the one that will ensure the best treatment results.

28 June 2023 in Health Problems of Civilization
Verified
Journal Article
Open access
VZValerii Zakharychev
Valerii Zakharychev
PGProkip Gordiichuk
Prokip Gordiichuk
MGMykola Gordiichuk
Mykola Gordiichuk
Background: Primary tumors of the mediastinum and chest wall are heterogeneous in morphological structure, united only by anatomical localization. Considering their proximity to the vital structures of the mediastinum, their treatment is a complex task that requires a personalized approach in the selection of neoadjuvant therapy. Material and methods: The results of surgical, combined and complex treatment of 1,375 patients with primary malignant tumors of the mediastinum, and 98 patients with malignant tumors of the chest wall were analyzed. Various treatment methods were used in the neoadjuvant regime: radiotherapy, thermoradiotherapy, chemoradiotherapy and intra-arterial regional chemotherapy. Results: The results proved that the use of intra-arterial neoadjuvant chemotherapy (IACT) has a better degree of tumor regression (p<0.05) and the lowest frequency of metastases compared with the use of radiotherapy and thermoradiotherapy (p0.05). The results of 3-year and 5-year survival rate did not have a statistically significant difference (p>0.05) between the variants of neoadjuvant therapy. Conclusions: In the treatment of patients with malignant tumors of the mediastinum and chest wall, the use of neoadjuvant therapy is mandatory. When a malignant tumor is localized in the anterior mediastinum, anterior and side wall of the chest, in the blood circulation zone of a. thoracica interna, a promising variant of neoadjuvant therapy is intra-arterial regional chemotherapy.